National Journal, February 15, 2023: NCHR joins lawmakers and other advocates in urging FDA and NIH to improve diversity in race/ethnicity, age, and sex in clinical trials as a way to improve medical care for everyone. So far, enforcement is lacking.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
American women still can’t get birth control pills without a prescription. This company has been trying for nine years to change that
FORTUNE, February 10, 2023: A company wants their birth control pill to be available over the counter. Is it safe enough to use without a prescription? It is safer than most hormonal contraceptives, but would this set a dangerous precedent for less safe contraceptives?
Read More »Many pediatric drug study results were never posted to a U.S. government database
STAT News, January 24, 2023: Results of 43 clinical trials involving thousands of children were never reported to clinicaltrials.gov or published in a medical journal or otherwise made publicly available, as required by law. We explain how this harms children and families.
Read More »Reassuring Safety Inquiry But Botched Comms Leads To Mixed Headlines For Pfizer Bivalent Vax
Pink Sheet, January 16, 2023: FDA and CDC failed to be transparent regarding their analysis of whether the Pfizer bivalent COVID vaccine increase strokes in older patients. There seems to be disagreement about how to explain the findings and the bottom line is that the agencies “don’t want to be asked questions” by experts in public.
Read More »Medicare, patient advocates at odds over coverage for an expensive new Alzheimer’s therapy
PoliticoPro, January 18, 2023: Public health and patient advocates disagree on whether Medicare should cover Leqembi, a questionable new treatment for Alzheimer’s Disease. We express doubts that the benefits outweigh the risks and the Patient, Consumer and Public Health Coalition urges Medicare to restrict coverage to clinical trials as they do for Aduhelm.
Read More »